Denosumab

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Castrate-resistant Prostate Cancer

Conditions

Castrate-resistant Prostate Cancer

Trial Timeline

Jan 1, 2011 → Feb 1, 2014

NCT ID

NCT01824342

About Denosumab

Denosumab is a phase 3 stage product being developed by Amgen for Castrate-resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01824342. Target conditions include Castrate-resistant Prostate Cancer.

What happened to similar drugs?

0 of 1 similar drugs in Castrate-resistant Prostate Cancer were approved

Approved (0) Terminated (1) Active (0)

❌custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisoneAchieve Life SciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03925532	Phase 2	Completed	Dec 19, 2019	Nov 16, 2022	Allogeneic Hematopoietic Stem Cell Transplantation Recipient
NCT03839459	Phase 2	Completed	Apr 19, 2019	Jan 30, 2025	Smoldering Multiple Myeloma
NCT03605199	Phase 2	UNKNOWN	Jun 18, 2018	Jun 1, 2023	Aneurysmal Bone Cysts
NCT03164928	Phase 3	Completed	May 7, 2018	Dec 20, 2023	Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With
NCT03301857	Approved	Completed	Nov 13, 2017	Jul 27, 2023	Giant Cell Tumor of Bone
NCT03070002	Phase 2	Terminated	Oct 19, 2017	Apr 24, 2018	Breast Carcinoma Metastatic in the Bone
NCT02613416	Phase 2	Completed	Nov 1, 2015	Aug 20, 2021	Breast Cancer
NCT02352753	Phase 3	Terminated	Jun 24, 2015	Mar 26, 2022	Osteogenesis Imperfecta
NCT02435147	Pre-clinical	Completed	Apr 1, 2015	Jun 1, 2016	Osteoporosis
NCT01952054	Phase 2	Terminated	Feb 9, 2015	Oct 10, 2018	Breast Cancer
NCT02129699	Phase 3	Terminated	Jan 6, 2015	Feb 29, 2020	Lung Cancer Non-small Cell Stage IV
NCT02099461	Phase 1	Completed	Apr 1, 2014	Jul 1, 2014	Healthy Volunteer, Female, Breast
NCT01869686	Phase 1	Completed	Jun 1, 2013	Sep 1, 2013	Healthy Volunteer
NCT01545648	Phase 2	Terminated	Nov 1, 2012	Jun 9, 2016	Early Stage Breast Cancer
NCT01652690	Pre-clinical	Completed	Jun 26, 2012	May 15, 2015	Osteoporosis, Postmenopausal
NCT01558115	Approved	Terminated	Jan 1, 2012	Oct 1, 2014	Primary Hyperparathyroidism
NCT01358669	Phase 2	Completed	Dec 14, 2011	Dec 31, 2021	Revision Surgery of Total Hip Arthroplasty
NCT01419717	Phase 3	Completed	Nov 22, 2011	Aug 10, 2018	Bone Metastases in Men With Hormone-Refractory Prostate Cancer
NCT01464931	Phase 1	Completed	Nov 1, 2011	Mar 1, 2013	Renal Impairment
NCT01824342	Phase 3	Completed	Jan 1, 2011	Feb 1, 2014	Castrate-resistant Prostate Cancer

Competing Products

9 competing products in Castrate-resistant Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
eFT508	eFFECTOR Therapeutics	Phase 2	17
AZD4635 + Durvalumab + Cabazitaxel	AstraZeneca	Phase 2	35
Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363	AstraZeneca	Phase 1	29
Part A: AZD8186 monotherapy + Part B: AZD8186 monotherapy + Part C1: Abiraterone acetate combination with AZD8186 + Part D1: AZD2014 combination with AZD8186 + Part D2 AZD2014 combination with AZD8186 + Part C2: Abiraterone acetate combination with AZD8186	AstraZeneca	Phase 1	29
BEZ235 + Prednisone + Abiraterone acetate	Novartis	Phase 1/2	24
Atezolizumab + Radium-223 Dichloride	Roche	Phase 1	29
Alobresib + Enzalutamide	Gilead Sciences	Phase 1/2	24
ISIS EIF4E Rx + ISIS EIF4E Rx + ISIS EIF4E Rx + Prednisone + Docetaxel	Ionis Pharmaceuticals	Phase 1/2	29
custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisone	Achieve Life Sciences	Phase 3	22